$1.1 Billion is the total value of Vivo Capital, LLC's 53 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 1425.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ASND | New | Ascendis Pharma A/Sadr | $225,574,000 | – | 2,003,147 | +100.0% | 20.44% | – |
| NFH | New | New Frontier Health Corp | $117,975,000 | – | 14,300,000 | +100.0% | 10.69% | – |
| KDMN | New | Kadmon Holdings Inc | $52,541,000 | – | 12,539,515 | +100.0% | 4.76% | – |
| ARQT | New | Arcutis Biotherapeutics Inc | $50,259,000 | – | 1,686,527 | +100.0% | 4.55% | – |
| CRNX | New | Crinetics Pharmaceuticals Inc | $48,816,000 | – | 3,320,801 | +100.0% | 4.42% | – |
| ZYME | New | Zymeworks Inc | $39,061,000 | – | 1,101,236 | +100.0% | 3.54% | – |
| SVA | New | Sinovac Biotech Ltd. | $38,173,000 | – | 5,900,000 | +100.0% | 3.46% | – |
| FTSV | New | Forty Seven Inc | $37,757,000 | – | 395,691 | +100.0% | 3.42% | – |
| PASG | New | Passage Bio Inc | $35,116,000 | – | 2,229,587 | +100.0% | 3.18% | – |
| AVDL | New | Avadel Pharmaceuticals PLCadr | $28,389,000 | – | 3,575,424 | +100.0% | 2.57% | – |
| ARWR | New | Arrowhead Pharmaceuticals Inc | $22,115,000 | – | 768,674 | +100.0% | 2.00% | – |
| ZGNX | New | Zogenix Inc | $21,978,000 | – | 888,724 | +100.0% | 1.99% | – |
| VSTM | New | Verastem Inc | $21,488,000 | – | 8,139,535 | +100.0% | 1.95% | – |
| SELB | New | Selecta Biosciences Inc | $18,910,000 | – | 7,846,509 | +100.0% | 1.71% | – |
| SRRA | New | Sierra Oncology, Inc | $18,826,000 | – | 1,917,074 | +100.0% | 1.70% | – |
| AKRO | New | Akero Therapeutics Inc | $17,135,000 | – | 808,247 | +100.0% | 1.55% | – |
| CDXS | New | Codexis, Inc | $16,672,000 | – | 1,493,903 | +100.0% | 1.51% | – |
| AMRS | New | Amyris, Inc | $16,620,000 | – | 6,492,247 | +100.0% | 1.51% | – |
| KRTX | New | Karuna Therapeutics Inc | $16,106,000 | – | 223,692 | +100.0% | 1.46% | – |
| MEIP | New | MEI Pharma Inc | $15,753,000 | – | 9,784,422 | +100.0% | 1.43% | – |
| FIXX | New | Homology Medicines, Inc. | $15,673,000 | – | 1,008,562 | +100.0% | 1.42% | – |
| MYOK | New | Myokardia Inc | $15,640,000 | – | 333,621 | +100.0% | 1.42% | – |
| ADRO | New | Aduro Biotech Inc | $14,025,000 | – | 5,118,560 | +100.0% | 1.27% | – |
| ORTX | New | Orchard Therapeutics plcads | $12,253,000 | – | 1,627,225 | +100.0% | 1.11% | – |
| EIGR | New | Eiger BioPharmaceuticals Inc | $12,181,000 | – | 1,791,257 | +100.0% | 1.10% | – |
| RCKT | New | Rocket Pharmaceuticals Inc | $12,006,000 | – | 860,648 | +100.0% | 1.09% | – |
| KNSA | New | Kiniksa Pharmaceuticals | $11,750,000 | – | 759,050 | +100.0% | 1.06% | – |
| TCDA | New | Tricida, Inc. | $11,534,000 | – | 524,290 | +100.0% | 1.04% | – |
| ZLAB | New | Zai Lab Limitedadr | $11,434,000 | – | 222,107 | +100.0% | 1.04% | – |
| KALV | New | KalVista Pharmaceuticals Inc. | $11,297,000 | – | 1,476,796 | +100.0% | 1.02% | – |
| IGMS | New | IGM Biosciences Inc | $11,209,000 | – | 199,626 | +100.0% | 1.02% | – |
| AVRO | New | Avrobio Inc | $11,168,000 | – | 717,753 | +100.0% | 1.01% | – |
| MNLO | New | Menlo Therapeutics Inc. | $10,301,000 | – | 3,843,824 | +100.0% | 0.93% | – |
| New | Trillium Therapeutics Inc | $8,300,000 | – | 2,054,468 | +100.0% | 0.75% | – | |
| COLL | New | Collegium Pharmaceutical Inc | $7,302,000 | – | 447,173 | +100.0% | 0.66% | – |
| AUPH | New | Aurinia Pharmaceuticals Inc. | $7,266,000 | – | 500,732 | +100.0% | 0.66% | – |
| KALA | New | Kala Pharmaceuticals, Inc. | $6,917,000 | – | 786,883 | +100.0% | 0.63% | – |
| MTNB | New | Matinas Biopharma Hldgs Inc | $6,770,000 | – | 11,279,323 | +100.0% | 0.61% | – |
| BDTX | New | Black Diamond Therapeutics Inc | $6,290,000 | – | 252,119 | +100.0% | 0.57% | – |
| VRNA | New | Verona Pharma PLCads | $6,151,000 | – | 1,492,951 | +100.0% | 0.56% | – |
| SLNO | New | Soleno Therapeutics, Inc. | $4,811,000 | – | 2,021,377 | +100.0% | 0.44% | – |
| CHMA | New | Chiasma Inc | $4,643,000 | – | 1,272,156 | +100.0% | 0.42% | – |
| XENE | New | Xenon Pharmaceuticals Inc | $4,497,000 | – | 396,589 | +100.0% | 0.41% | – |
| CNST | New | Constellation Pharmaceutical | $4,410,000 | – | 140,298 | +100.0% | 0.40% | – |
| RVMD | New | Revolution Medicines Inc | $4,371,000 | – | 199,518 | +100.0% | 0.40% | – |
| GLMD | New | Galmed Pharmaceuticals Ltd | $2,976,000 | – | 860,103 | +100.0% | 0.27% | – |
| ATRC | New | Atricure Inc | $2,169,000 | – | 64,573 | +100.0% | 0.20% | – |
| ACRS | New | Aclaris Therapeutics, Inc. | $1,713,000 | – | 1,647,214 | +100.0% | 0.16% | – |
| CBAY | New | Cymabay Therapeutics Inc | $1,595,000 | – | 1,077,467 | +100.0% | 0.14% | – |
| QURE | New | Uniqure NV | $1,088,000 | – | 22,932 | +100.0% | 0.10% | – |
| DBVT | New | DBV Technologies S.A.adr | $1,058,000 | – | 269,995 | +100.0% | 0.10% | – |
| New | Nabriva Therapeutics AG | $980,000 | – | 1,704,130 | +100.0% | 0.09% | – | |
| DTIL | New | Precision Biosciences Inc | $846,000 | – | 140,255 | +100.0% | 0.08% | – |
| Exit | Verona Pharma PLC925050106 | $0 | – | -2,805,035 | -100.0% | -1.94% | – | |
| Exit | Sinovac Biotech Ltd.p8696w104 | $0 | – | -9,610,156 | -100.0% | -3.45% | – | |
| Exit | Zai Lab Limited98887q104 | $0 | – | -2,552,237 | -100.0% | -21.76% | – | |
| Exit | Zymeworks Incg6461g106 | $0 | – | -101,392,395 | -100.0% | -72.85% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACLARIS THERAPEUTICS INC | 29 | Q3 2023 | 33.5% |
| CODEXIS INC | 29 | Q3 2023 | 8.0% |
| ASCENDIS PHARMA A/S | 25 | Q3 2022 | 24.0% |
| KALVISTA PHARMACEUTICALS INC | 25 | Q3 2023 | 3.9% |
| Verona Pharma PLC ADR | 24 | Q3 2023 | 7.6% |
| AMYRIS INC | 23 | Q3 2023 | 8.8% |
| EIGER BIOPHARMACEUTICALS INC | 23 | Q1 2022 | 8.7% |
| Zai Lab Ltd ADR | 22 | Q3 2023 | 1.8% |
| Arrowhead Pharmaceuticals Inc | 21 | Q3 2023 | 6.9% |
| HOMOLOGY MEDICINES INC | 21 | Q3 2023 | 3.7% |
View Vivo Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SINOVAC BIOTECH LTDSold out | August 27, 2018 | 0 | 0.0% |
View Vivo Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-04-22 |
| 13F-HR | 2024-02-07 |
| 13F-HR | 2023-11-08 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Vivo Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.